Cargando…

Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors

Mutations in succinate dehydrogenase B (SDHB) gene are frequently observed in several tumors and associated with poor prognosis in these tumors. Therefore, drugs effective for SDHB-deficient tumors could fulfill an unmet medical need. In addition, such drugs would have an advantage in that selection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitazawa, Satoshi, Ebara, Shunsuke, Ando, Ayumi, Baba, Yuji, Satomi, Yoshinori, Soga, Tomoyoshi, Hara, Takahito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438703/ https://www.ncbi.nlm.nih.gov/pubmed/28423651 http://dx.doi.org/10.18632/oncotarget.15959

Ejemplares similares

Discovery of Benzo[d]imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
por: Cipriano, Alessandra, et al.
Publicado: (2022)

Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
por: Wu, Dayu, et al.
Publicado: (2022)

Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
por: Li, Feng, et al.
Publicado: (2020)

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
por: Trivedi, Archit, et al.
Publicado: (2020)

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
por: Kulikowski, Ewelina, et al.
Publicado: (2020)

Prognostic role of overexpressed Bromodomain and extra-terminal family in ovarian cancer
por: Chetry, Mandika, et al.
Publicado: (2022)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
por: Flynn, Noah R., et al.
Publicado: (2021)

Succinate dehydrogenase‐deficient malignant paraganglioma complicated by succinate dehydrogenase‐deficient renal cell carcinoma
por: Yamaguchi, Yoshitomo, et al.
Publicado: (2022)

Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis
por: Fu, Rong, et al.
Publicado: (2022)

Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins
por: Chabert, Clovis, et al.
Publicado: (2017)

Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
por: Bian, Benjamin, et al.
Publicado: (2019)

Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
por: Sun, Hui-Yan, et al.
Publicado: (2022)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
por: Nguyen, Martin V., et al.
Publicado: (2020)

Cancer with low cathepsin D levels is susceptible to vacuolar (H(+))‐ATPase inhibition
por: Kitazawa, Satoshi, et al.
Publicado: (2017)

Succinic Semialdehyde Dehydrogenase Deficiency: An Update
por: Didiasova, Miroslava, et al.
Publicado: (2020)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease
por: Manni, Michelle L., et al.
Publicado: (2017)

Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia
por: Carrà, Giovanna, et al.
Publicado: (2019)

Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
por: Lai, Jiacheng, et al.
Publicado: (2021)

Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors
por: Chen, Siao, et al.
Publicado: (2021)

Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN
por: Shi, Xiyao, et al.
Publicado: (2022)

Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation
por: Martella, Noemi, et al.
Publicado: (2023)

Regulation of inflammatory genes in decidual cells: Involvement of the bromodomain and extra-terminal family proteins
por: Ajgaonkar, Sandeep, et al.
Publicado: (2023)

Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors
por: Okegawa, Takatsugu, et al.
Publicado: (2017)

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors
por: Wadhwa, Elizabeth, et al.
Publicado: (2016)

Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members
por: Malik, Nazma, et al.
Publicado: (2015)

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
por: Alqahtani, Ali, et al.
Publicado: (2019)

Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors
por: Groves, Andrew, et al.
Publicado: (2022)

Succinate Dehydrogenase Deficiency Is Rare in Pituitary Adenomas
por: Gill, Anthony J., et al.
Publicado: (2014)

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors
por: Wong, C, et al.
Publicado: (2014)

Cardiac‐specific succinate dehydrogenase deficiency in Barth syndrome
por: Dudek, Jan, et al.
Publicado: (2015)

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
por: Belinsky, Martin G., et al.
Publicado: (2017)

Rapamycin as a potential treatment for succinate dehydrogenase deficiency
por: Fan, Frances, et al.
Publicado: (2019)

Succinate Dehydrogenase Deficiency: A Treatable Neurometabolic Disorder
por: KARIMZADEH, Parvaneh, et al.
Publicado: (2020)

Succinic semialdehyde dehydrogenase deficiency presenting with central hypothyroidism
por: Alghamdi, Malak Ali, et al.
Publicado: (2020)

Bromodomain and extra-terminal (BET) proteins target Moloney murine leukemia virus integration to transcription start sites
por: De Riick, Jan, et al.
Publicado: (2013)

Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function
por: Pinz, Sophia, et al.
Publicado: (2015)

77232 The role of the bromodomain and extra-terminal motif (BET) family of proteins in head and neck cancer tumorigenic phenotype
por: Sample, Reilly A., et al.
Publicado: (2021)

Succinate Dehydrogenase Deficiency in Pediatric and Adult Gastrointestinal Stromal Tumors
por: Belinsky, Martin G., et al.
Publicado: (2013)

Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors
por: Zhao, Yue, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k8unuhrv2b8eom433unp0j5phb